STOCK TITAN

Rezolute, Inc. - $RZLT STOCK NEWS

Welcome to our dedicated page for Rezolute news (Ticker: $RZLT), a resource for investors and traders seeking the latest updates and insights on Rezolute stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Rezolute's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Rezolute's position in the market.

Rhea-AI Summary
Rezolute, Inc. has received PRIME eligibility from the European Medicines Agency for its drug candidate RZ358, which is being developed for the treatment of congenital hyperinsulinism. The EMA has recognized the unmet medical need for this condition and the potential benefits of RZ358 for patients. This eligibility was granted based on positive data from the Phase 2b RIZE study, which showed significant improvements in hypoglycemia events and time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.52%
Tags
none
-
Rhea-AI Summary
Rezolute announces positive results of RZ358 treatment for refractory hypoglycemia in patients with tumor-mediated hyperinsulinism
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6%
Tags
none
-
Rhea-AI Summary
Rezolute, Inc. plans to initiate Phase 3 study for RZ358 in Q4 2023. Results expected in H1 2025. Phase 2 study of RZ402 to have results in Q1 2024. Cash and equivalents of $16.0M and investments of $102.3M as of June 30, 2023. R&D expenses increased from FY2022 to FY2023. Net loss increased from FY2022 to FY2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Rezolute CEO to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.38%
Tags
-
Rhea-AI Summary
Stonegate Healthcare Partners releases thematic report on innovative advancements in the treatment of diabetic eye disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.35%
Tags
none
Rhea-AI Summary
Rezolute, Inc. announces financial results for Q3 2023 and progress in pipeline
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.44%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rezolute, Inc.

Nasdaq:RZLT

RZLT Rankings

RZLT Stock Data

117.17M
22.39M
20.45%
77.72%
0.64%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
REDWOOD CITY

About RZLT

rezolute is a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies to improve the lives of patients with metabolic and orphan diseases. rezolute is advancing a diversified pipeline including: rz358 (phase 2), an antibody for the ultra-orphan indication of congenital hyperinsulinism (chi) with an abbreviated path-to-market strategy; ab101 (phase 1), a once-weekly injectable basal insulin with the potential to transform the treatment landscape in diabetes management by reducing the therapeutic burden for patients and improving compliance; and rz402 (plan to file ind in h2 2018), a plasma kallikrein inhibitor (pki) targeting diabetic macular edema (dme). for more information, visit: www.rezolutebio.com.